Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.

Authors

Guru Sonpavde

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL

Guru Sonpavde , Gregory Russell Pond , Arnoud J. Templeton , Eugene D. Kwon , Johann S. De Bono

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 Genitourinary Cancers Symposium

bookmark_border

Predicting toxicity-related docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer (mCRPC) using open phase III trial data.

First Author: Anish B. Parikh

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC).

First Author: Matthew Raymond Smith

insert_chart_outlined

Poster

2014 Genitourinary Cancers Symposium

bookmark_border

Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).

First Author: Robert Dreicer

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.

First Author: Neal D. Shore